Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition. The approval was based on results from the phase 3 REVISIT trial. The FDA has ...

Drug utilization study using antibacterial agents consumption data. The groups of antibacterial agents most consumed in the hospital complex were carbapenems, penicillins + beta-lactamase inhibitors, ...